Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H3N2O4.K |
| Molecular Weight | 194.1866 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].[O-]C(=O)C1=CC(=O)NC(=O)N1
InChI
InChIKey=DHBUISJCVRMTAZ-UHFFFAOYSA-M
InChI=1S/C5H4N2O4.K/c8-3-1-2(4(9)10)6-5(11)7-3;/h1H,(H,9,10)(H2,6,7,8,11);/q;+1/p-1
| Molecular Formula | C5H3N2O4 |
| Molecular Weight | 155.0883 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | K |
| Molecular Weight | 39.0983 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Potassium Orotate is a non-steroidal anabolic preparation with regenerating, diuretic effect. Potassium Orotate improves appetite, cardiac glycosides tolerance, stimulates regenerative and reparative processes of metabolism. Orotic acid is one of precursors the pyrimidine nucleotides which are a part of nucleic acids which participate in synthesis of protein molecules. In this regard potassium orotate is applied as substance of anabolic action at disturbances of protein metabolism, first of all at disturbance of albumin function of a liver, at the dystrophic changes in a myocardium which developed as owing to pathological process (a myocarditis, myocardial infarction), and as a result of a physical overstrain in sport as the general stimulators of metabolic processes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0032774 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Potassium orotate Approved UsePotassium orotate is prescribed for diseases / conditions:
Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia);
Alimentary-infection and alimentary dystrophy in children;
Hyperlipidemia;
Atherosclerosis;
Anemia;
As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver;
Spastic conditions (including angiospasm);
Myocardial dystrophy;
Progressive muscular dystrophy;
Increased physical activity;
Dermatoses. |
|||
| Primary | Potassium orotate Approved UsePotassium orotate is prescribed for diseases / conditions:
Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia);
Alimentary-infection and alimentary dystrophy in children;
Hyperlipidemia;
Atherosclerosis;
Anemia;
As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver;
Spastic conditions (including angiospasm);
Myocardial dystrophy;
Progressive muscular dystrophy;
Increased physical activity;
Dermatoses. |
|||
| Primary | Potassium orotate Approved UsePotassium orotate is prescribed for diseases / conditions:
Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia);
Alimentary-infection and alimentary dystrophy in children;
Hyperlipidemia;
Atherosclerosis;
Anemia;
As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver;
Spastic conditions (including angiospasm);
Myocardial dystrophy;
Progressive muscular dystrophy;
Increased physical activity;
Dermatoses. |
|||
| Primary | Potassium orotate Approved UsePotassium orotate is prescribed for diseases / conditions:
Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia);
Alimentary-infection and alimentary dystrophy in children;
Hyperlipidemia;
Atherosclerosis;
Anemia;
As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver;
Spastic conditions (including angiospasm);
Myocardial dystrophy;
Progressive muscular dystrophy;
Increased physical activity;
Dermatoses. |
|||
| Primary | Potassium orotate Approved UsePotassium orotate is prescribed for diseases / conditions:
Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia);
Alimentary-infection and alimentary dystrophy in children;
Hyperlipidemia;
Atherosclerosis;
Anemia;
As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver;
Spastic conditions (including angiospasm);
Myocardial dystrophy;
Progressive muscular dystrophy;
Increased physical activity;
Dermatoses. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [The influence of 'potassium orotate' on neocollagenogenesis in implantation of polypropylene endoprosthesis and polypropylene combined with polylactic acid endoprosthesis]. | 2017-04-05 |
|
| [Psychophysiological effects of combined administration of pantogam and potassium orotate in patients with neurotic disorders]. | 2001-09-18 |
|
| [The treatment results in patients with gouty nephropathy]. | 1990-06 |
|
| [Structure of the liver after correction of experimental chronic hepatitis with benzonal and potassium orotate]. | 1990-02 |
|
| [Quantitative evaluation of the anxiolytic and nootropic effects of potassium orotate in a wide range of doses]. | 1986-01-01 |
Sample Use Guides
In Vivo Use Guide
Sources: http://en.remedy-info.com/kalija-orotat.html
Potassium orotate taken internally 2-3 times a day for 250-500 mg. The drug is recommended to take 1 hour before meals or 4 hours after.
Duration of therapy - 20-40 days, if necessary, the course can be repeated in a month.
Children are usually prescribed 10-20 mg / kg per day, the frequency of reception is 2-3 times a day. The duration of the treatment course is 21-35 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:52:26 GMT 2025
by
admin
on
Mon Mar 31 17:52:26 GMT 2025
|
| Record UNII |
6ZDN9W1C9W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB14989MIG
Created by
admin on Mon Mar 31 17:52:26 GMT 2025 , Edited by admin on Mon Mar 31 17:52:26 GMT 2025
|
PRIMARY | |||
|
DTXSID0067004
Created by
admin on Mon Mar 31 17:52:26 GMT 2025 , Edited by admin on Mon Mar 31 17:52:26 GMT 2025
|
PRIMARY | |||
|
100000078843
Created by
admin on Mon Mar 31 17:52:26 GMT 2025 , Edited by admin on Mon Mar 31 17:52:26 GMT 2025
|
PRIMARY | |||
|
23665705
Created by
admin on Mon Mar 31 17:52:26 GMT 2025 , Edited by admin on Mon Mar 31 17:52:26 GMT 2025
|
PRIMARY | |||
|
24598-73-0
Created by
admin on Mon Mar 31 17:52:26 GMT 2025 , Edited by admin on Mon Mar 31 17:52:26 GMT 2025
|
PRIMARY | |||
|
246-341-0
Created by
admin on Mon Mar 31 17:52:26 GMT 2025 , Edited by admin on Mon Mar 31 17:52:26 GMT 2025
|
PRIMARY | |||
|
8602
Created by
admin on Mon Mar 31 17:52:26 GMT 2025 , Edited by admin on Mon Mar 31 17:52:26 GMT 2025
|
PRIMARY | RxNorm | ||
|
6ZDN9W1C9W
Created by
admin on Mon Mar 31 17:52:26 GMT 2025 , Edited by admin on Mon Mar 31 17:52:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |